Table 2 Cohort characteristics.
Age | Primary tumor localization (n, %) | Number of lesions (n, %) | |||
Median (yrs) | 49.2 | Limb | 126 (50.2) | 1 | 114 (45.4) |
Range | 16.1–85.6 | Trunk/spine | 43 (17.1) | 2 | 45 (17.9) |
(n, %) | Retroperitoneum | 15 (6.0) | 3 | 27 (10.8) | |
< 45 | 111 (44.2) | Uterus | 15 (6.0) | 4 | 14 (5.6) |
45–55 | 44 (17.5) | Other | 47 (18.7) | 5 | 7 (2.8) |
56–60 | 28 (11.2) | Unknown | 5 (2.0) | > 5 | 41 (16.3) |
> 60 | 68 (27.1) | Unknown | 3 (1.2) | ||
Gender (n, %) | Initial tumor size (cm) | TTBM (mo) | |||
Male | 142 (56.6) | Median | 9 | Median | 18.48 |
Female | 109 (43.4) | Range | 1–36 | Range | 0–215.34 |
ECOG Performance Status (PS) (n, %) | Karnofsky Performance Status (KPS) (n. %) | BM localization (n, %) | |||
0 | 47 (18.7) | 90–100 | 67 (26.7) | Supra-tentorial | 122 (48.6) |
1 | 69 (27.5) | 70–80 | 77 (30.7) | Infra-tentorial | 12 (4.8) |
2 | 56 (22.3) | 50–60 | 57 (22.7) | Both | 71 (28.3) |
3 | 51 (20.3) | < 40 | 39 (15.5) | ||
4 | 17 (6.8) | Unknown | 11 (4.4) | Meningeal | 24 (9.5) |
Unknown | 11 (4.4) | Meningeal & parenchymal | 16 (6.4) | ||
Unknown | 6 (2.4) | ||||
Type of sarcoma (n, %) | Extracranial metastasis (n, %) | TMtBM (mo) | |||
Soft tissue | 207 (82.47) | No | 23 (9.2) | Median | 9.6 |
Bone | 44 (17.53) | Yes | 228 (90.8) | Range | 0–110.8 |
Grade (n. %) | Lung | 184 (73.3) | Chemotherapy lines prior to BM (n, %) | ||
1 | 7 (2.8) | Liver | 36 (14.3) | Median | 1 |
2 | 41 (16.4) | Bone | 62 (24.7) | Range | 0–7 |
3 | 118 (47.0) | Other | 76 (30.3) | At least 1 line | 185 (73.7) |
Unknown | 85 (33.8) | ||||
Histology (n, %) | WBRT (n, %) | Intrathecal chemotherapy (n, %) | |||
Leiomyosarcoma | 46 (18.3) | Yes | 147 (58.6) | Yes | 3 (1.2) |
Ewing/PNET | 30 (12.0) | No | 99 (39.4) | No | 242 (96.4) |
Liposarcoma | 19 (7.6) | Unknown | 5 (2.0) | Unknown | 6 (2.4) |
ASPS | 14 (5.6) | SRS (n, %) | Best response to BM treatment (n, %) | ||
Osteosarcoma | 14 (5.6) | Yes | 24 (9.6) | CR | 18 (7.2) |
Rhabdomyosarcoma | 14 (5.6) | No | 221 (88.0) | PR | 31 (12.3) |
Angiosarcoma | 14 (5.6) | Unknown | 6 (2.4) | SD | 64 (25.5) |
Synovialosarcoma | 13 (5.1) | PD | 119 (47.4) | ||
Uncertain differentiation/Other | 82 (32.6) | Unknown/not evaluable | 19 (7.6) | ||
Unknown | 5 (2.0) | ||||
Chemotherapy for BM (n, %) | Surgery (n, %) | Follow-up (mo) | |||
Yes | 91 (36.2) | Yes | 39 (15.5) | Median | 2.7 |
No | 154 (61.4) | No | 206 (82.1) | Range | 0.1–133.0 |
Unknown | 6 (2.4) | Unknown | 6 (2.4) |